CRISPR Therapeutics AG reports developments in gene-based medicines built around CRISPR/Cas9 gene editing, cell therapy, in vivo editing and siRNA programs. Recurring updates cover CASGEVY, developed with Vertex for severe sickle cell disease and transfusion-dependent beta thalassemia, as well as pipeline work in cardiovascular disease, autoimmune disease, oncology, rare disease and Type 1 diabetes.
Company news also includes financial results, business updates, investor conference presentations, manufacturing and platform disclosures, collaborations such as Sirius Therapeutics, and capital actions involving common shares or convertible senior notes.
CRISPR Therapeutics (NASDAQ: CRSP) and Sirius Therapeutics have announced the dosing of the first patient in a Phase 2 clinical trial of SRSD107, their co-developed Factor XI (FXI) siRNA therapy for preventing venous thromboembolism in total knee arthroplasty patients.
SRSD107 demonstrated promising results in Phase 1 trials, showing over 93% reduction in FXI levels and a twofold increase in aPTT relative to baseline. The treatment's effects were sustained for up to six months post-dosing, suggesting potential for semi-annual administration.
The therapy aims to address limitations of current anticoagulants by reducing pathological thrombosis while minimizing bleeding risk. The addressable market includes patients with atrial fibrillation, VTE, cancer-associated thrombosis, and various cardiovascular conditions where bleeding risk currently limits treatment options.
CRISPR Therapeutics (Nasdaq: CRSP) announced it will present late-breaking data at the American Heart Association (AHA) Scientific Sessions 2025 in New Orleans, Louisiana, from November 7-10, 2025.
The company will showcase two key presentations: A late-breaking oral presentation on Phase 1 clinical data for CTX310™, their CRISPR/Cas9 gene editing therapy targeting ANGPTL3 for cardiovascular and cardiometabolic disease, and a poster presentation on CTX340™, their preclinical program targeting angiotensinogen for refractory hypertension treatment.
The presentations are scheduled for November 8, 2025, with the CTX310 data presented at 8:30 a.m. CST and the CTX340 poster at 2:30 p.m. CST. Presentation materials will be available on the company's website after the sessions.
CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company specializing in gene-based medicines, has announced its participation in two major investor conferences in September 2025.
The company will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8 at 4:30 p.m. ET and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9 at 8:30 a.m. ET. Live webcasts will be available on the company's website, with replays accessible for 14 days after the presentations.
CRISPR Therapeutics (NASDAQ:CRSP) reported its Q2 2025 financial results and business updates, highlighting significant progress across its commercial and clinical programs. The company's flagship product CASGEVY® has achieved its target of activating 75 authorized treatment centers globally, with ~115 patients completing cell collection and 29 receiving infusions.
Key clinical developments include CTX310™ showing promising preliminary data with up to 82% reduction in triglycerides and 86% in LDL, and ongoing trials for CTX112™ and CTX131™ in oncology and autoimmune diseases. The company maintains a strong financial position with $1.7 billion in cash and equivalents, despite reporting a net loss of $208.5 million for Q2 2025.
CRISPR Therapeutics (NASDAQ: CRSP) has been named to TIME's 100 Most Influential Companies list for 2025 in the Pioneers category. The recognition highlights the company's groundbreaking work in gene editing and its expansion beyond treating sickle cell disease and beta thalassemia into cardiovascular and autoimmune diseases.
The selection process involved TIME editors evaluating companies based on impact, innovation, ambition, and success, with input from global contributors, correspondents, and external experts. CEO Samarth Kulkarni emphasized the company's mission to transform medicine through science and innovation, viewing the recognition as validation of their team's dedication to advancing genetic medicine.
CRISPR Therapeutics (NASDAQ: CRSP) has reported positive additional Phase 1 data for its cardiovascular drug candidate CTX310, targeting ANGPTL3. The trial demonstrated impressive dose-dependent reductions of up to 82% in triglycerides and 86% in LDL, with a well-tolerated safety profile.
The company plans to present complete Phase 1 data for CTX310 in H2 2025. Additionally, CRISPR provided updates on two other cardiovascular programs: CTX320 targeting LPA gene, with data now expected in H1 2026, and CTX340 for refractory hypertension, which is advancing toward IND/CTA filings.
CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company specializing in gene-based medicines, has announced its participation in two major investor conferences in June 2025. The company's senior management will present at William Blair's 45th Annual Growth Stock Conference on June 3 at 11:20 a.m. CT and at the Goldman Sachs' 46th Annual Global Healthcare Conference on June 9 at 3:20 p.m. ET. Live webcasts will be available on the company's website, with replays accessible for 14 days after the presentations.
CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company specializing in gene-based medicines, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference. The company's senior management team will conduct a fireside chat on Tuesday, April 8, 2025, at 12:45 p.m. ET.
The presentation will be accessible through a live webcast on the company's investor relations website under the 'Events & Presentations' section. Interested parties can access the replay of the webcast, which will remain available for 14 days after the presentation.